Interim 2024/25 influenza vaccine effectiveness: eight European studies, September 2024 to January 2025.
Saved in:
| Title: | Interim 2024/25 influenza vaccine effectiveness: eight European studies, September 2024 to January 2025. |
|---|---|
| Authors: | Rose AM; Epiconcept, Paris, France.; These authors contributed equally as first authors.; These authors contributed equally to the writing of the paper., Lucaccioni H; Epiconcept, Paris, France.; These authors contributed equally as first authors., Marsh K; Public Health Scotland, NHS Scotland, Glasgow, United Kingdom., Kirsebom F; UK Health Security Agency, London, England., Whitaker H; UK Health Security Agency, London, England., Emborg HD; Department of Infectious Disease Epidemiology and Prevention, Statens Serum Institut, Copenhagen, Denmark., Bolt Botnen A; Department of Virology and Microbiological Preparedness, Statens Serum Institut, Copenhagen, Denmark., O'Doherty MG; Public Health Agency, Belfast, United Kingdom., Pozo F; Consortium for Biomedical Research in Epidemiology and Public Health (CIBERESP), Madrid, Spain.; National Centre for Microbiology, Institute of Health Carlos III, Madrid, Spain., Hameed SS; Public Health Scotland, NHS Scotland, Glasgow, United Kingdom., Andrews N; UK Health Security Agency, London, England., Hamilton M; Public Health Scotland, NHS Scotland, Glasgow, United Kingdom., Trebbien R; Department of Virology and Microbiological Preparedness, Statens Serum Institut, Copenhagen, Denmark., Lauenborg Møller K; Data Integration and Analyses, Statens Serum Institut, Copenhagen, Denmark., Marques DF; Epiconcept, Paris, France., Murphy S; Public Health Agency, Belfast, United Kingdom., McQueenie R; Public Health Scotland, NHS Scotland, Glasgow, United Kingdom., Lopez-Bernal J; UK Health Security Agency, London, England., Cottrell S; Public Health Wales, Cardiff, Wales., Bucholc M; Public Health Agency, Belfast, United Kingdom., Kissling E; Epiconcept, Paris, France.; These authors contributed equally to the writing of the paper. |
| Corporate Authors: | European IVE group; European Influenza Vaccine Effectiveness (IVE) group members are listed under Collaborators., Members of the European IVE group |
| Source: | Euro surveillance : bulletin Europeen sur les maladies transmissibles = European communicable disease bulletin [Euro Surveill] 2025 Feb; Vol. 30 (7). |
| Publication Type: | Journal Article |
| Journal Info: | Publisher: European Centre for Disease Prevention and Control (ECDC) Country of Publication: Sweden NLM ID: 100887452 Publication Model: Print Cited Medium: Internet ISSN: 1560-7917 (Electronic) Linking ISSN: 1025496X NLM ISO Abbreviation: Euro Surveill Subsets: MEDLINE |
| Database: | MEDLINE Ultimate |
Be the first to leave a comment!
